1. Home
  2. FRPH vs OMER Comparison

FRPH vs OMER Comparison

Compare FRPH & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FRP Holdings Inc.

FRPH

FRP Holdings Inc.

HOLD

Current Price

$21.11

Market Cap

420.6M

Sector

Finance

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$20.05

Market Cap

844.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRPH
OMER
Founded
1986
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
420.6M
844.6M
IPO Year
1995
2008

Fundamental Metrics

Financial Performance
Metric
FRPH
OMER
Price
$21.11
$20.05
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $32.50
AVG Volume (30 Days)
93.7K
★ 1.5M
Earning Date
04-10-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 98.15
EPS
N/A
★ 0.77
Revenue
★ $42,846,000.00
$29,868,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$233.22
P/E Ratio
★ N/A
$26.14
Revenue Growth
★ 2.57
N/A
52 Week Low
$20.53
$4.06
52 Week High
$25.74
$21.24

Technical Indicators

Market Signals
Indicator
FRPH
OMER
Relative Strength Index (RSI) 35.14 61.99
Support Level $20.78 $18.00
Resistance Level $23.10 N/A
Average True Range (ATR) 0.46 0.88
MACD -0.06 0.02
Stochastic Oscillator 7.69 73.95

Price Performance

Historical Comparison
FRPH
OMER

About FRPH FRP Holdings Inc.

FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, industrial, and office (the Development Segment), and (iv) management of mixed-use residential/retail properties owned through joint ventures.

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Share on Social Networks: